Company Overview of The Multiple Myeloma Research Foundation, Inc
Key Executives for The Multiple Myeloma Research Foundation, Inc
Chief Executive Officer, President and Chief Operating Officer
Founder and Executive Chairman
Vice President of Communications
Chief Development and Marketing Officer
Compensation as of Fiscal Year 2014.
The Multiple Myeloma Research Foundation, Inc Key Developments
The Multiple Myeloma Research Foundation, Inc Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 04:00 PM
Feb 22 15
The Multiple Myeloma Research Foundation, Inc Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 04:00 PM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Speakers: Daniel Auclair, Vice President, Translational Research.
Inflection Biosciences Ltd Announces Collaboration with The Multiple Myeloma Research Foundation
Feb 9 15
Inflection Biosciences Ltd. announced a collaboration with the Multiple Myeloma Research Foundation on pre-clinical testing of its innovative dual mechanism PIM/PI3K inhibitor IBL-202. PIM and PI3K are two key regulators in signalling pathways that have proved essential for the proliferation and survival of myeloma cells. The MMRF investigators will test the effectiveness of IBL-202 alone and in combination with other therapeutics in pre-clinical models of multiple myeloma. These models are recognised to be predictive of clinical efficacy in cancer patients with multiple myeloma. IBL-202 is a dual mechanism kinase inhibitor that selectively inhibits PIM and PI3K without affecting the activity of other kinases. MMRF support will greatly assist in further evaluating the potential of IBL-202 for patients with multiple myeloma, one of the many indications hope to consider. The MMRF is working with Inflection Biosciences through its Translational Network of Excellence program, which supports critical research at leading academic medical centers focused on promising investigational therapies for multiple myeloma.
The Multiple Myeloma Research Foundation and GNS Healthcare Announce Collaboration to Identify Potential New Multiple Myeloma Therapies
Jan 7 15
GNS Healthcare announced a collaboration to speed the discovery of innovative treatments for patients with multiple myeloma. The effort will combine the unprecedented genomic and clinical data from the MMRF's CoMMpass Study with revolutionary GNS machine learning platforms and rapid computer simulations. The work supports the development of computer models of myeloma disease that may uncover novel molecular pathways that can prevent progression of disease and address the unmet treatment needs of patients with multiple myeloma. CoMMpass is a longitudinal study of 1,000 newly diagnosed patients with active multiple myeloma. Its objective is to map each of these patients genomic profiles to clinical outcomes to develop a more complete understanding of patient responses to treatments. GNS will use an in silico process, applying its MAX architecture and patented REFS inference engine and simulation platforms to the CoMMpass data. REFS will identify causal drivers and underlying molecular processes of disease progression. REFS will also discover the most likely targets for therapeutics to treat, and perhaps to predict and prevent, relapses and refractory disease. REFS will also discover predictive diagnostic biomarkers that determine which treatments will work and for which patients. The work promises to support physicians and patients with a broader set of individualized treatment protocols mapped to specific molecular and genomic characteristics. GNS has used REFS successfully to advance the research priorities of numerous nonprofit organizations focused on diseases including Huntington’s disease, multiple sclerosis, childhood asthma, Alzheimer's disease and others. Its work ultimately enables next-generation care management solutions focused on reducing adverse events, slowing disease progression and improving therapeutic effectiveness through precision medicine.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries